OVERVIEW

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Recent News

More>>
  • Nov 08, 2017

    GAITHERSBURG, Md. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced the Company will present at the Stifel 2017 Healthcare Conference. Presentation details are as follows: Date: Wednesday, November 15, 2017 Time: 1:15 p.m. – 1:55 p.m....More>>

  • Nov 07, 2017

    GAITHERSBURG, Md. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq:NVAX) today announced its financial results for the third quarter and nine months ended September 30, 2017 . Third Quarter Achievements: Novavax initiated a Phase 1/2 clinical trial of its nanoparticle influenza vaccine...More>>

  • Oct 31, 2017

    GAITHERSBURG, Md. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its third quarter financial and operating results following the close of U.S. financial markets on Tuesday, November 7, 2017 . Conference call details are as follows: Date: Tuesday,...More>>

Stock Quote